Nicholas Davies

1.5k citations

25 papers · 1000 indexed · h-index 15

Co-authors: Tatjana Stanković Christopher M. Bunce J.P. Ride Angelo Agathanggelou Marwan Kwok Grant S. Stewart Edward Smith Eva Petermann
Topics: Chronic Lymphocytic Leukemia Research (7 papers)Aldose Reductase and Taurine (5 papers)Cancer-related Molecular Pathways (4 papers)
Cited by: Cell Biology Oncology Genetics
Journals: The Lancet Blood Molecular Cell
Partner nations: United Kingdom United States Germany

In The Last Decade

Nicholas Davies

24 papers receiving 988 citations

Peers

Countries citing papers authored by Nicholas Davies

Since Specialization

Citations

This map shows the geographic impact of Nicholas Davies's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Davies with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Davies more than expected).

Fields of papers citing papers by Nicholas Davies

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Davies. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Davies. The network helps show where Nicholas Davies may publish in the future.

Co-authorship network of co-authors of Nicholas Davies

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Davies. A scholar is included among the top collaborators of Nicholas Davies based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Davies. Nicholas Davies is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives 2021 ·Cancers ·Marwan Kwok,Angelo Agathanggelou,Nicholas Davies,Tatjana Stanković	14
2	Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts 2017 ·Oncotarget ·Nicholas Davies,Marwan Kwok,(unknown),Ceri Oldreive,(unknown),Helen Parry,Edward Smith,Angelo Agathanggelou,Guy Pratt,A. Malcolm R. Taylor,Paul Moss,Mike Griffiths,Tatjana Stanković	10
3	A Network Biology Approach Identifies Molecular Cross-Talk between Normal Prostate Epithelial and Prostate Carcinoma Cells 2016 ·PLoS Computational Biology ·Víctor Treviño,(unknown),Zsuzsanna Nagy,Xiaodong Zhuang,John Herbert,(unknown),Kim Clarke,Nicholas Davies,Ayesha Rahman,Moray J. Campbell,Michele Guindani,Roy Bicknell,Marina Vannucci,Francesco Falciani	3
4	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells 2015 ·Blood ·Marwan Kwok,Nicholas Davies,Angelo Agathanggelou,Edward Smith,Ceri Oldreive,Eva Petermann,Grant S. Stewart,(unknown),Alan Lau,Guy Pratt,Helen Parry,A. Malcolm R. Taylor,Paul Moss,Peter Hillmen,Tatjana Stanković	211
5	Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway 2015 ·The Lancet ·Marwan Kwok,Nicholas Davies,Angelo Agathanggelou,Edward Smith,Eva Petermann,(unknown),Jeffrey S. Brown,Alan Lau,Tatjana Stanković	69
6	BOD1L Is Required to Suppress Deleterious Resection of Stressed Replication Forks 2015 ·Molecular Cell ·Martin R. Higgs,John J. Reynolds,Alicja Winczura,Andrew N. Blackford,Valérie Borel,Edward S. Miller,Anastasia Zlatanou,Jadwiga Nieminuszczy,Ellis L. Ryan,Nicholas Davies,Tatjana Stanković,Simon J. Boulton,Wojciech Niedźwiedź,Grant S. Stewart	148
7	T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice 2015 ·Disease Models & Mechanisms ·Ceri Oldreive,Anna Skowrońska,Nicholas Davies,Helen Parry,Angelo Agathanggelou,Sergey Krysov,Graham Packham,Zbigniew Rudzki,(unknown),Katerina Vrzalikova,Paul G. Murray,Elena Odintsova,Guy Pratt,A. Malcolm R. Taylor,Paul Moss,Tatjana Stanković	6
8	ATR Inhibition Exacerbates Replication Stress in TP53 or ATM Deficient CLL Cells and Enhances Sensitivity to Chemotherapy and Targeted Therapy 2014 ·Blood ·Marwan Kwok,Nicholas Davies,Angelo Agathanggelou,Edward Smith,Eva Petermann,(unknown),Jeffrey S. Brown,Alan Lau,Tatjana Stanković	1
9	Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate 2014 ·British Journal of Cancer ·Farhat L. Khanim,Nicholas Davies,Pedro Veliça,Rachel Hayden,J.P. Ride,Chathyan Pararasa,Mei Chong,Ulrich L. Günther,Natacha Veerapen,Peter J. Winn,Rohit Farmer,Elisabeth Trivier,Laurent Rigoreau,Mark T. Drayson,Christopher M. Bunce	27
10	PMO-134 Basal cell adhesion molecule and b1-integrins regulate the adhesion of ES cell-derived hepatocye-like cells to extracellular matrix and hepatic sinusoidal cells 2012 ·Gut ·Nicholas Davies,(unknown),(unknown),Patricia F. Lalor,David Adams,David C. Hay,Philip N. Newsome	2
11	Human mesenchymal stem cells are recruited to injured liver in a β1-integrin and CD44 dependent manner 2012 ·Hepatology ·(unknown),(unknown),Nicholas Davies,David Bartlett,Janine Youster,(unknown),Dean Kavanagh,Neena Kalia,Jon Frampton,Patricia F. Lalor,Philip N. Newsome	56
12	The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis 2009 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Jane Birtwistle,Rachel E. Hayden,Farhat L. Khanim,Richard M. Green,(unknown),Nicholas Davies,N. Wake,(unknown),J.P. Ride,J.K. Chipman,Christopher M. Bunce	68
13	Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers 2009 ·Molecular Cancer ·Pedro Veliça,Nicholas Davies,Pedro P. Rocha,Heinrich Schrewe,J.P. Ride,Christopher M. Bunce	63
14	Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia 2009 ·PLoS ONE ·Farhat L. Khanim,Rachel E. Hayden,Jane Birtwistle,Alessia Lodi,Stefano Tiziani,Nicholas Davies,Jon P. Ride,Mark R. Viant,Ulrich L. Günther,Joanne C. Mountford,Heinrich Schrewe,Richard M. Green,J. A. H. Murray,Mark T. Drayson,Christopher M. Bunce	63
15	Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dΔ12,14,PGJ2 2008 ·Leukemia ·Richard E. Hayden,Guy Pratt,Nicholas Davies,Farhat L. Khanim,Jane Birtwistle,Julio Delgado,(unknown),(unknown),Mark T. Drayson,Christopher M. Bunce	29
16	Targeting Antigen-loaded Liposomes to Myeloid Antigen Presenting Cells 2005 ·Queensland's institutional digital repository (The University of Queensland) ·Christelle Capini,Montree Jaturanpinyo,Anand M. Gautam,Nicholas Davies,Ranjeny Thomas	0
17	Making Sense of Molecular Signatures in The Immune System 2004 ·Combinatorial Chemistry & High Throughput Screening ·Nicholas Davies,Mahlet G. Tadesse,Marina Vannucci,(unknown),Víctor Treviño,Donatella Sarti,I. Dragoni,Andrea Contestabile,Edward D. Zanders,Francesco Falciani	2
18	Interpretation of rubella serology in pregnancy—pitfalls and problems 2002 ·BMJ ·Jennifer M. Best,Siobhan O’Shea,Graham Tipples,Nicholas Davies,(unknown),Amanda Krause,Louise Hesketh,Li Jin,Gisela Enders	50
19	Octreotide inhibits the growth and development of three types of experimental liver metastases 1995 ·British journal of surgery ·Nicholas Davies,Howard Kynaston,J Yates,David Nott,Jennifer Nash,B A Taylor,S A Jenkins	13
20	Early results with the Lichtenstein tension-free hernia repair 1994 ·British journal of surgery ·Nicholas Davies,Mark J. Thomas,(unknown),A N Kingsnorth	17

About Nicholas Davies

Nicholas Davies is a scholar working on Genetics, Hepatology and Cell Biology, having authored 25 papers that have together received 1000 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (7 papers), Aldose Reductase and Taurine (5 papers) and Cancer-related Molecular Pathways (4 papers). The work is most often cited by research in Cell Biology (191 citations), Oncology (298 citations) and Genetics (116 citations). Nicholas Davies has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Tatjana Stanković, Christopher M. Bunce, J.P. Ride, Angelo Agathanggelou, Marwan Kwok, Grant S. Stewart, Edward Smith, Eva Petermann, Alan Lau and Jane Birtwistle. Their work appears in journals such as The Lancet, Blood and Molecular Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact